Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.